Figure 2
Figure 2. Increased tumor growth and vascularization of Fgfr-1−/− teratomas. (A) Growth of Fgfr-1+/− and Fgfr-1−/− teratomas in NMRI-nu mice. (B) The volume of the teratomas was determined regularly by measuring with a caliper, allowing estimation of the teratoma growth rate (mm3/day). The difference in growth rate between Fgfr-1+/− and Fgfr-1−/− teratomas was statistically different; *P = .007. (C) Staining of teratoma sections for CD31 expression (red). Bars represent 50 μm. (D) Quantification of the CD31+ area in Fgfr-1+/− and Fgfr-1−/− teratomas. The CD31+ area was significantly increased (*P = .002) in the Fgfr-1−/− teratomas.

Increased tumor growth and vascularization of Fgfr-1−/− teratomas. (A) Growth of Fgfr-1+/− and Fgfr-1−/− teratomas in NMRI-nu mice. (B) The volume of the teratomas was determined regularly by measuring with a caliper, allowing estimation of the teratoma growth rate (mm3/day). The difference in growth rate between Fgfr-1+/− and Fgfr-1−/− teratomas was statistically different; *P = .007. (C) Staining of teratoma sections for CD31 expression (red). Bars represent 50 μm. (D) Quantification of the CD31+ area in Fgfr-1+/− and Fgfr-1−/− teratomas. The CD31+ area was significantly increased (*P = .002) in the Fgfr-1−/− teratomas.

Close Modal

or Create an Account

Close Modal
Close Modal